Osgenic Oy

Based in Finland, Osgenic Oy specializes in orthopedic education, offering innovative digital resources for surgical training and anatomical understanding to medical professionals across the globe. Osgenic Oy, founded in 2017 and headquartered in Helsinki, Finland, focuses on providing educational solutions for orthopedic professionals. The company has completed 3 deals, the most recent on April 20, 2021. In July 2023, Springvest Oy became a key investor by raising EUR 5 million for Osgenic, bringing the total amount raised to EUR 5 million.

The company is led by Founder and CEO Arne Schlenzka, who has a history in entrepreneurial ventures within the medical education space. Osgenic is a leading platform specializing in orthopedic education, offering a comprehensive suite of resources designed to enhance surgical training and understanding of anatomy. Central to their offerings is the Osgenic platform, which integrates video demonstrations of surgical procedures, detailed surgical plans, and virtual anatomy models that facilitate learning for medical professionals. Targeted primarily at orthopedic residents, fellows, and institutions, the platform is utilized in over 100 countries, enhancing the educational experience in both hospital and academic settings.

By combining high-quality imagery and illustrations with interactive content, Osgenic serves a diverse clientele, including medical schools, orthopedic departments, and residency programs, ensuring that users have access to the latest information and techniques in adult reconstructive surgery and other orthopedic specialties. Osgenic operates on a subscription-based revenue model, offering both monthly and annual membership options. For the year 2023, the company reported a revenue of EUR 33,983. 50 and an EBITDA of EUR -1,772,920.

80. The monthly membership is priced at EUR 19. 90, granting users unlimited access to the platform's extensive content library, including new releases and the ability to create personalized anatomy illustrations through its Invivo anatomy feature. Transactions typically occur directly between Osgenic and individual users or institutional clients, with the firm also promoting institutional access for hospitals and medical schools, allowing for bulk subscriptions.

Each membership includes a 14-day free trial, enabling prospective users to explore the platform's value before committing to a paid subscription. In July 2023, Osgenic Oy secured EUR 5 million in venture funding from Springvest Oy, which will be directed towards enhancing their platform and expanding product offerings. Future plans include the introduction of new features and resources aimed at improving the educational tools available to orthopedic professionals. The company is also considering expansion into new markets, specifically targeting regions in North America and Asia by the end of 2024, to further increase accessibility and user engagement with their products.